Dendritic cell sarcoma, not otherwise specifi ed (NOS), is an entity that is poorly defi ned because of its rarity and poorly understood pathogenesis. It is characterized by positive immunohistochemical staining for S-100 and CD1a, along with an absence of cytoplasmic Birbeck granules on electron microscopy. We report the case of a surgically inaccessible nasopharyngeal dendritic cell sarcoma, NOS, in a 34-year-old man. Treatment with chemotherapy along with adjuvant radiation therapy was successful in decreasing the size of the nasopharyngeal mass, and the patient remained free of any evidence of recurrence nearly 5 years aft er treatment.
Introduction
Dendritic cells are a heterogeneous group of nonlymphoid and nonphagocytic immune accessory cells that are present in lymphoid and nonlymphoid organs. 1 Th ey belong to a group of immunoregulatory cells that are responsible for antigen processing and presentation to lymphocytes. Neoplasms of dendritic cell origin are exceedingly rare, accounting for fewer than 1% of all tumors of the lymph nodes. 2 As a result, information regarding their epidemiology and treatment, as well as the prognosis of aff ected patients, is scarce. 3, 4 We present the case of a patient who was found to have a dendritic cell sarcoma, not otherwise specifi ed (NOS), aft er he presented with ENT complaints and weight loss.
Case report
A 34-year-old man presented to an outside emergency department with complaints of diffi culty breathing through his nose, dysphagia with solids, ear pain, and a 25-lb weight loss over the preceding month. Physical examination revealed the presence of small neck masses bilaterally. Th e results of laboratory testing were noncontributory. Th e patient was treated as having a tooth abscess and sent home. He subsequently returned to the same emergency department six times before he was eventually referred to a local otorhinolaryngologist for evaluation.
At the ENT offi ce examination, nasal endoscopy detected a large, mucosa-covered mass that had obstructed 60 to 70% of the left choana; the mass also extended past the midline to obstruct part of the right choana. No other lesions were noted, and vocal fold function was normal. At this point, the patient was referred to our institution for further assessment and treatment.
Computed tomography (CT) of the neck with contrast identifi ed enlarged and matted lymph nodes bilaterally from levels I through V; many of these nodes demonstrated central necrosis (fi gure 1). Magnetic resonance imaging (MRI) without contrast showed a heterogeneous right nasopharyngeal mass (fi gure 2, A), which demonstrated intense fl uorodeoxyglucose (FDG) uptake on corresponding F18-fl uorodeoxyglucose-positron-emission tomography/computed tomography (FDG-PET/CT) (fi gure 2, B). FDG-PET/CT also demonstrated FDG uptake in the cervical, supraclavicular, infraclavicular, and axillary lymph nodes.
Th e nasopharyngeal mass was biopsied, and microscopic examination identifi ed it as a diff usely infi ltrating tumor made up of cells that exhibited enlarged and irregular vesicular nuclei with variably prominent nucleoli. An infl ammatory infi ltrate composed primarily of lymphocytes was interspersed within the tumor. Areas blastine, and dacarbazine (ABVD). Aft er the second cycle, however, his lymphadenopathy seemed to be progressing clinically; this was confi rmed by CT, which also identifi ed newly enlarged mediastinal and hilar lymph nodes. He was referred for radiation therapy while docetaxel and gemcitabine were added to his chemotherapy regimen. Aft er the change in treatment, the size of the nasopharyngeal mass and lymph nodes began to decrease.
Nearly 5 years aft er the completion of chemo-and radiotherapy, the patient remained free of any evidence of recurrence on MRI. He did experience a few complications of treatment-including unilateral Horner syndrome, mild dysphagia, and neck pain-but overall he did well and reported no new complaints. of necrosis and frequent mitotic fi gures were also present. Immunohistochemical studies showed focal expression of CD68 with moderate to strong staining for S-100 (fi gure 3, A), CD1a (fi gure 3, B), vimentin, and lysozyme. Stains for AE1/AE3, epithelial membrane antigen (EMA), monoclonal carcinoembryonic antigen (CEA), leukocyte common antigen (LCA), MART1, HMB45, CD21, CD35, CD30, E-cadherin, chromogranin, desmoplakin, and muscle-specifi c actin were all negative. At this point, a diagnosis of either Langerhans cell sarcoma or dendritic cell sarcoma was favored.
Th e pathology service requested more tissue so that further studies could be conducted. Another biopsy was performed, and electron microscopy revealed large dendritic cells with indented nuclei along with many mitochondria, lysosomes, and endoplasmic reticuli (fi gure 4). Interdigitating cell processes with desmosomes characteristic of dendritic cells were also seen. No Birbeck granules were present. Based on the positive immunohistochemical stains for S-100 and CD1a and the absence of Birbeck granules, a fi nal diagnosis of dendritic cell sarcoma, NOS, was declared.
Th e patient underwent two cycles of chemotherapy with doxorubicin (Adriamycin), bleomycin, vin- 
Figure 1. A: Coronal CT of the neck with contrast demonstrates the bilaterally enlarged cervical lymph nodes from levels I through V and the involvement of the supraclavicular fossae bilaterally. B: Axial CT with contrast demonstrates the enlarged level II lymph nodes on the right (thin arrow) and left (thick arrow), along with prominent central necrosis.

Discussion
Th e World Health Organization categorizes dendritic cell neoplasms into fi ve groups: Langerhans cell histiocytosis/ sarcoma, histiocytic sarcoma, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, and dendritic cell sarcoma, NOS. 5 Dendritic cell sarcoma, NOS, is a diagnosis of exclusion, as it is not well characterized morphologically or immunohistochemically. 6 Th e neoplastic cells typically express S-100 and CD1a, but they lack cytoplasmic Birbeck granules. 5 Although most dendritic cell sarcomas arise in lymph nodes-especially those in the cervical, mediastinal, and axillary areas-approximately one-third of cases involve extranodal sites. Th ese neoplasms are slightly more common in men than women (ratio: 1.4:1), and they aff ect a wide range of ages (14 to 80 yr). 7 Th e behavior of these tumors is similar to that of low-grade soft -tissue sarcomas, and the risk of developing a local recurrence and/or a distant metastasis approaches 30%. 7 Tumors that arise from dendritic cells are quite rare. In a study published in 2006, Morton et al reviewed 136,985 cases of hematopoietic neoplasms and found that only 122 (0.09%) were histiocytic or dendritic cell tumors. 8 Th eir overall incidence was only 0.03%.
Th e diff erentiation of dendritic cell sarcoma, NOS, from other dendritic cell neoplasms is based on morphology and immunohistochemistry. Dendritic cell sarcomas, NOS, are typically positive for S-100 and CD1a, and they lack Birbeck granules on electron microscopy. 5 In contrast, interdigitating dendritic cell sarcomas, follicular dendritic cell sarcomas, and histiocytic sarcomas are all CD1a-negative. 9 Moreover, while Langerhans cell sarcomas are also positive for both S-100 and CD1a, they are characterized by the presence of Birbeck granules on electron microscopy. 1 To the best of our knowledge, ours is the fi rst reported case of a dendritic cell sarcoma, NOS, with such diffuse radiologic fi ndings, and the fi rst that involved the treatment of a dendritic cell sarcoma, NOS, that was not surgically resectable. In fact, we were able to fi nd only 1 other case of a dendritic cell sarcoma, NOS, reported in the literature. 10 In that particular report, the authors described a composite tumor in which a dendritic cell sarcoma, NOS, and a small lymphocytic lymphoma were present within the same lymph node.
Although the clinical presentation and sites of in- volvement vary among the diff erent types of dendritic cell neoplasms, a poor prognosis is a common feature because of disease spread and a poor response to therapy. 9 Adverse prognostic factors include an intra-abdominal site, a tumor size larger than 6 cm, the presence of extensive necrosis or cytologic atypia, and a high proliferative index suggesting high mitotic activity. 11 Complete surgical resection is considered to be the treatment of choice for surgically accessible lesions. 12 Other therapeutic options include chemotherapy and radiation therapy, although the results of chemotherapy in the treatment of some dendritic cell neoplasms have been poor. 3, 13 Unfortunately, the nasopharyngeal mass in our patient was not surgically accessible, and he demonstrated a poor response to ABVD chemotherapy because his lymphadenopathy seemed to be progressing aft er two cycles. However, he experienced more promising results when docetaxel and gemcitabine were added to his treatment regimen along with radiation therapy, and the size of his aff ected lymph nodes subsequently decreased. He remained disease-free at nearly 5 years of follow-up.
